Gefitinib and Epidermal Growth Factor Receptor Gene Copy Number Aberrations in Esophageal Cancer
Purpose: The cancer esophagus gefitinib (COG) trial demonstrated improved progression free survival with the Epidermal Growth Factor Receptor (EGFR) tyrosine kinase inhibitor (TKI), gefitinib relative to placebo in advanced esophageal cancer patients with disease progression after chemotherapy. Rapi...
| Main Authors: | , , , , |
|---|---|
| Format: | Journal article |
| Published: |
American Society of Clinical Oncology
2017
|